Otsuka’s Promising Drug Advances in Kidney Disease Trial
Company Announcements

Otsuka’s Promising Drug Advances in Kidney Disease Trial

Otsuka Holdings Co (JP:4578) has released an update.

Otsuka Holdings Co. has reported positive interim results from their Phase 3 trial of sibeprenlimab, a promising treatment for immunoglobulin A nephropathy in adults. The trial demonstrated a significant reduction in urine protein levels and maintained a favorable safety profile, paving the way for a potential accelerated approval submission to the FDA. Final results are anticipated in early 2026.

For further insights into JP:4578 stock, check out TipRanks’ Stock Analysis page.

Related Articles
TipRanks Japan Auto-Generated NewsdeskOtsuka Holdings Expands into North American IV Market
TipRanks Auto-Generated NewsdeskOtsuka Holdings Reports Strong Nine-Month Financial Growth
TipRanks Japan Auto-Generated NewsdeskOtsuka Holdings Co. Announces Leadership Transition
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App